RT Journal Article
T1 Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
A1 Retamar, Pilar
A1 López-Cerero, Lorena
A1 Muniain, Miguel Angel
A1 Pascual, Álvaro
A1 Rodríguez-Baño, Jesús
K1 Antibacterianos
K1 Estudios de cohortes
K1 Quimioterapia combinada
K1 Infecciones por escherichia coli
K1 Pruebas de sensibilidad microbiana
K1 Ácido senicilánico
K1 Infecciones urinarias
AB We investigated the impact of the piperacillin-tazobactam MIC in the outcome of 39 bloodstream infections due to extended-spectrum-β-lactamase-producing Escherichia coli. All 11 patients with urinary tract infections survived, irrespective of the MIC. For other sources, 30-day mortality was lower for isolates with a MIC of ≤ 2 mg/liter than for isolates with a higher MIC (0% versus 41.1%; P = 0.02).
PB American Society for Microbiology
SN 0066-4804
YR 2013
FD 2013-07
LK http://hdl.handle.net/10668/2160
UL http://hdl.handle.net/10668/2160
LA en
NO Retamar P, López-Cerero L, Muniain MA, Pascual Á, Rodríguez-Baño J, Gijón P, et al. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob. Agents Chemother. 2013; 57(7):3402-4
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 12, 2025